Tocilizumab for the treatment of rheumatoid arthritis

Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody, which binds to circulating soluble IL-6 receptor and membrane-expressed IL-6 receptor, inhibiting IL-6 binding to both forms of IL-6 receptor. Several Phase III clinical trials demonstrate the clinical efficacy of tocilizumab as monotherapy or with disease-modifying anti-rheumatic drugs for adult patients with moderately to severely active rheumatoid arthritis. Tocilizumab in combination with methotrexate after 24 weeks of treatment could induce disease remission in 30% of patients with rheumatoid arthritis refractory to anti-TNF antagonist therapy. The most common adverse reactions reported in clinical studies are upper respiratory tract infection, nasopharyngitis, headache, hypertension and mild, reversible increases in alanine aminotransferase enzymes. Serious adverse reactions include infections, gastrointestinal perforations and hypersensitivity reactions, including anaphylaxis. The clinical efficacy and safety of tocilizumab has led to the approval of this innovative drug for the treatment of rheumatoid arthritis in more than 70 countries worldwide.

[1]  M. Kawai,et al.  The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab , 2010, Rheumatology.

[2]  L. Kanz,et al.  Mixed response to tocilizumab for ankylosing spondylitis , 2010, Annals of the rheumatic diseases.

[3]  M. Gaubitz,et al.  Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Einsatz von Tocilizumab bei der rheumatoiden Arthritis (Februar 2010) , 2010, Zeitschrift für Rheumatologie.

[4]  R. Landewé,et al.  Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA , 2010, Annals of the rheumatic diseases.

[5]  K. Hagihara,et al.  Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica , 2010, The Journal of Rheumatology.

[6]  M. Kawai,et al.  Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens , 2010, Modern rheumatology.

[7]  K. Hagihara,et al.  Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. , 2010, Rheumatology.

[8]  H. Arima,et al.  Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis , 2010, Clinical Rheumatology.

[9]  N. Nishimoto,et al.  Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions , 2010, Modern rheumatology.

[10]  P. Lipsky,et al.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. , 2010, Arthritis and rheumatism.

[11]  M. Genovese,et al.  Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study , 2009, Annals of the rheumatic diseases.

[12]  K. Migita,et al.  Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD). , 2010, Clinical and experimental rheumatology.

[13]  J. Smolen,et al.  Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlle , 2010, Arthritis and rheumatism.

[14]  J. Branco,et al.  Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update. , 2010, Acta reumatologica portuguesa.

[15]  M. Gaubitz,et al.  [Recommendations of the German rheumatology society on the use of tocilizumab in rheumatoid arthritis]. , 2010, Zeitschrift fur Rheumatologie.

[16]  M. Kawai,et al.  Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. , 2009, Arthritis and rheumatism.

[17]  R. Moots,et al.  Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the ‘age of remission’? , 2009, Expert opinion on investigational drugs.

[18]  N. Miyasaka,et al.  Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis , 2009, Modern rheumatology.

[19]  M. Kawai,et al.  Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment , 2009, Annals of the rheumatic diseases.

[20]  H. Ishikawa,et al.  Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis , 2009, Clinical Rheumatology.

[21]  M. Scheinberg,et al.  Anti-interleukin 6: first line in rheumatoid arthritis? , 2009, Clinical Rheumatology.

[22]  J. Hashimoto,et al.  A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years , 2009, Modern rheumatology.

[23]  M. Iwamoto,et al.  Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab , 2009, Clinical Rheumatology.

[24]  N. Miyasaka,et al.  Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study , 2008, Annals of the rheumatic diseases.

[25]  Kazuhiko Yamamoto,et al.  Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy , 2008, Modern rheumatology.

[26]  M. Kawai,et al.  Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. , 2008, Rheumatology.

[27]  B. Saint-Marcoux,et al.  Tocilizumab for multirefractory adult-onset Still’s disease , 2008, Annals of the rheumatic diseases.

[28]  D. Soolingen,et al.  Mycobacterial disease in patients with rheumatic disease , 2008, Nature Clinical Practice Rheumatology.

[29]  N. Nishimoto,et al.  Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.

[30]  M. Weinblatt,et al.  When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? , 2008, Annals of the rheumatic diseases.

[31]  M. Genovese,et al.  Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. , 2008, Arthritis and rheumatism.

[32]  J. Kremer,et al.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.

[33]  N. Nishimoto,et al.  Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. , 2008, Arthritis and rheumatism.

[34]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[35]  T. Kishimoto,et al.  The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. , 2008, Expert opinion on biological therapy.

[36]  Michael H Weisman,et al.  New therapies for treatment of rheumatoid arthritis , 2007, The Lancet.

[37]  D. M. van der Heijde,et al.  Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.

[38]  Portuguese guidelines for the use of biological agents in rheumatoid arthritis--December 2007 update. , 2007, Acta reumatologica portuguesa.

[39]  P. Emery,et al.  Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. , 2006, Arthritis and rheumatism.

[40]  Y. Okuda,et al.  Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. , 2006, Arthritis and rheumatism.

[41]  K. Hagihara,et al.  Essential role of STAT3 in cytokine‐driven NF‐κB‐mediated serum amyloid A gene expression , 2005, Genes to cells : devoted to molecular & cellular mechanisms.

[42]  L. Moreland.  Humanized anti-interleukin-6 receptor antibody , 2005 .

[43]  T. Kishimoto.  Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.

[44]  V. Rodríguez-Valverde,et al.  Outcome of late-onset rheumatoid arthritis , 2005, Clinical Rheumatology.

[45]  N. Miyasaka,et al.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[46]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[47]  K. Hagihara,et al.  IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. , 2004, Biochemical and biophysical research communications.

[48]  T. Kishimoto,et al.  Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. , 2003, The Journal of rheumatology.

[49]  K. Yoshizaki,et al.  Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. , 2002, Arthritis and rheumatism.

[50]  R. Price,et al.  Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. , 2002, Arthritis and rheumatism.

[51]  Y. Saeki,et al.  Interleukin 6 plays a key role in the development of antigen-induced arthritis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Akira,et al.  Structure and function of a new STAT-induced STAT inhibitor , 1997, Nature.

[53]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[54]  C. Schindler.  Cytokine signal transduction. , 1995, Receptor.

[55]  R. Zinkernagel,et al.  Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.

[56]  O. Silvennoinen,et al.  Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Kellum,et al.  Interleukin 6 , 1994, Critical care medicine.

[58]  G. Yancopoulos,et al.  Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. , 1993, Blood.

[59]  K. Yasukawa,et al.  IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. , 1993, Science.

[60]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[61]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. , 1989, Blood.

[62]  T. Hirano,et al.  Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis , 1988, European journal of immunology.

[63]  T. Hirano,et al.  Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. , 1987, Proceedings of the National Academy of Sciences of the United States of America.